Traws Pharma (TRAW) announced completion of Phase I clinical studies of its investigational one-dose influenza therapy, tivoxavir marboxil, for the treatment or prevention of H5N1 bird flu. “We believe that our clinical data in healthy volunteers support accelerated development of tivoxavir marboxil in response to the growing threat of bird flu,” said Werner Cautreels, PhD, CEO of Traws Pharma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue